Medtronic Receives Notification of Activities Relating to INFUSE Bone Graft; FDA Receives Repros' Submission Androxal Print E-mail
By Staff and Wire Reports   
Wednesday, 16 May 2012 19:05
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 16, 2012.

Medtronic, Inc. (NYSE: MDT)
announced it has been notified by the U.S. Department of Justice (DOJ) and the Office of the United States Attorney for the District of Massachusetts that federal prosecutors have closed their investigation of Medtronic related to INFUSE® Bone Graft.

The status of this federal civil and criminal investigation has been regularly reported in Medtronic's quarterly disclosures.


Repros Therapeutics Inc.® (Nasdaq: RPRX)
announced it has received confirmation of delivery of the required documentation for Special Protocol Assessment of its Androxal® Phase 3 pivotal studies to the FDA. Per the Prescription Drug User Fee Act ("PDUFA"), the FDA has 45 calendar days to provide comments back to Repros.

Also Wednesday:

Agilent Technologies Inc. (NYSE:A)
today announced that a quarterly dividend of 10 cents per share of common stock will be paid on July 25 to all shareholders of record as of the close of business on July 3.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
today announced that updated clinical data from the pivotal PACE trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, June 1-5, 2012.

Array BioPharma Inc. (NASDAQ: ARRY)
today announced oral presentations on its two MEK inhibitors, selumetinib (AZD6244) and MEK162 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will held June 1-5, 2012 at McCormick Place in Chicago, Illinois.

and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1st line Advanced RCC), will be presented on June 2 in an oral session by the principal investigator, Robert J. Motzer, M.D., attending physician, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, professor of medicine, Weill Medical College, Cornell University, New York, at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Baxter International Inc. (NYSE:BAX)
today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration (SFDA).

Biovest International, Inc. (OTCQB:BVTI)
, a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that Biovest has retained Ferghana Partners as the Company’s strategic transaction advisor to evaluate/implement creative financings and partnering opportunities on a regional or global basis for BiovaxID®, its late-stage personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma.

Bristol-Myers Squibb Company (NYSE:BMY)
today announced that new data on its approved and investigational oncology compounds will be featured in ten oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST)
today announced that it has awarded nearly $300,000 in grants this year to benefit 16 organizations with science, technology, engineering, and mathematics (STEM) programs in Massachusetts.

CytoDyn Inc. (OTCQB:CYDY)
, a biotechnology company focused on the development of new therapies for combating infection with immune deficiency virus and other antibody applications, announced today that the Company completed production of a sufficient amount of CytoFeline™, a monoclonal antibody developed by the Company for the treatment of Feline Immunodeficiency Virus ("FIV"), to allow the Company, through its wholly owned subsidiary, CytoDyn Veterinary Medicine LLC ("CVM"), to move forward with the next stage of the antibody's development.

Dendreon Corporation (NASDAQ:DNDN)
today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5, 2012 in Chicago, Illinois.

Given Imaging Ltd. (NASDAQ: GIVN) today announced the results of its annual shareholders' meeting which was held yesterday in Yoqneam, Israel.

As awareness activities take place today across the globe in recognition of Hereditary Angioedema (HAE) Day –– Dyax Corp. (NASDAQ: DYAX) has announced a donation of $25,000 to the United States Hereditary Angioedema Association (HAEA) – the largest HAE patient group in the world.

Exelixis, Inc. (NASDAQ:EXEL)
reiterated its slate of activities in conjunction with the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-5, 2012, in Chicago, Illinois.

Fibrocell Science, Inc. (OTCBB: FCSC)
announced today that it has signed an exclusive license agreement with The Regents of the University of California, under which it acquired the rights to commercially apply discoveries resulting from the scientific collaboration between the University of California, Los Angeles (UCLA) and Fibrocell Science, Inc.

ImmunoGen, Inc. (NASDAQ: IMGN)
, a biotechnology company that develops targeted antibody-based anticancer products, today announced that there will be four presentations at the upcoming 2012 American College of Clinical Oncology (ASCO) Annual Meeting on compounds that utilize the Company’s Targeted Antibody Payload (TAP) technology.

Insmed Incorporated (Nasdaq CM: INSM)
, a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall Whitcomb, M.D. as the Lead Independent Director, effective immediately.  

International Stem Cell Corporation (OTCBB: ISCO)
( today announced financial results for the three months ended March 31, 2012.

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV)
, today announced that the Company’s Chief Science Officer, Edward Wirth III, MD, PhD will be presenting at the Interdependence 2012 show currently being held in Vancouver through May 17th, 2012.

Medtronic, Inc. (NYSE: MDT)
today announced it has been notified by the U.S. Department of Justice (DOJ) and the Office of the United States Attorney for the District of Massachusetts that federal prosecutors have closed their investigation of Medtronic related to INFUSE® Bone Graft.

Merck (NYSE: MRK)
, known as MSD outside the United States and Canada, announced today that Alex Kelly, senior vice president, investor relations, is scheduled to present at the Bank of America Merrill Lynch 2012 Healthcare Conference in Las Vegas, on May 17 at 11:40 a.m. EDT.

Mindray Medical International Limited (NYSE: MR)
, a leading developer, manufacturer and marketer of medical devices worldwide, announced today that HealthTrust Purchasing Group, L.P., (HealthTrust) is renewing its agreement for its full line of physiological patient monitoring equipment.

MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce representatives from the Company will present preclinical research findings for MCT-465 and MCT-485 at CIMT 2012 (, Europe's largest meeting dedicated to cancer immunotherapy research and development.

Marking a major milestone for the company, Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (, a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Israeli Patent Office.

Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing statistically significant advantages of using an IN.PACT drug-eluting balloon from Medtronic, Inc. (NYSE: MDT) over a corresponding conventional treatment for coronary and peripheral artery disease.

Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR)
announced today that its Board of Directors has increased the Company's common share repurchase program authorization by an additional 5 million shares.

Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL)
is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma.

Seattle Genetics, Inc. (NASDAQ:SGEN)
today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus